Market Overview

UPDATE: JP Morgan Upgrades Teva Pharmaceuticals

Share:
Related TEVA
Mylan Confirms USPTO Institutes Inter Partes Review Proceedings vs Two Copaxone 40 mg/mL Dosing Patents
The Coming Drug-Patent Cliff Is Pushing This Portfolio Up
Facebook, IBD 50's 5 Most Liquid Stocks Setting Up (Investor's Business Daily)

On Friday, JP Morgan upgraded shares of Teva Pharmaceuticals (NYSE: TEVA) from Underweight to Neutral and raised the profit target to $49.

Analyst Chris Schott is encouraged by “favorable initial Copaxone 3x weekly trends and the potential for additional cost cutting activity,” but remains “less enthusiastic around Teva's organic growth prospects and its P&L reliance on Copaxone.”

Schott expects Teva management's “willingness to consider larger business development opportunities will be well received.”

Shares of Teva are up 21 percent year-to-date and up 1.8 percent to $48.82 during Friday's session.

Latest Ratings for TEVA

DateFirmActionFromTo
Aug 2015Goldman SachsReinstatesBuy
Aug 2015JP MorganUpgradesNeutralOverweight
Jul 2015Leerink SwannMaintainsOutperform

View More Analyst Ratings for TEVA
View the Latest Analyst Ratings

Posted-In: Chris Schott JP MorganAnalyst Color Analyst Ratings

 

Related Articles (TEVA)

View Comments and Join the Discussion!

Get Benzinga's Newsletters